Neurotez Inc. on NetCapital

Neurotez Inc. is developing a drug to treat Leptin deficiency in Alzheimer’s patients.

Raise to date: $175,676

Reporting Date: 06/30/2020

Key Stats

Minimum Raise

$10,000

Maximum Raise

$500,000

Likelihood of Max Unlikely
Start Date

08/19/2019

Stop Date

07/16/2020

Days Remaining

13

Security Type

Common Stock

Investment Minimum

$2

Deal Type

Deal to Watch


Investment Summary

Status

Active

# of Investors

Not Known

% of Minimum Raised

1,757%

% of Maximum Raised

35%

Dollars Per Day to Reach Max

$24,948

DPD* Committed

$556

DPD* Category

$0

DPD* All Companies

$2,196

Kingscrowd Momentum

$175,676

Total Dollars Raised

Commitments

Weekly Commitments ($)
Aggregate Commitments ($)

SEC Filing Data from Kingscrowd

Neurotez, with a post-money valuation of $22.5 million, is raising funds on NetCapital. The company is developing a hormone replacement therapy named Memtin to treat Leptin deficiency in Alzheimer’s patients. The drug will help slow down the cognitive decline in Alzheimer’s patients and other forms of dementia. Neurotez is led by Nikolaos Tezapsidis as the President and CEO, and Wes Ashford as the Chief Medical Officer. The company has already raised $4.5 million in funding from the National Institute of Health, IRS, and New Jersey Commission of Science and Technology. The current crowdfunding round has a minimum goal of $10,000 and a maximum goal of $500,000, and the proceeds will be used for the various studies, clinical trials, manufacturing, personnel costs, and debt repayment. Neurotez has already received many rewards and recognitions and is backed by an excellent team of experts.

Create your first portfolio
WELCOME TO YOUR OWN INVESTMENTS PORTFOLIO ON KINGSCROWD.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Add Neurotez Inc. on NetCapital
Follow company
Follow Neurotez Inc. on NetCapital
INVEST NOW

Get access to the first and only premium analytics and rating platform that enables informed startup investments.

Become an Informed Investor